-
1
-
-
84884526776
-
The current state of HIV therapy
-
Benzer JA, et al. The current state of HIV therapy. Formulary 2013;48:213-223.
-
(2013)
Formulary
, vol.48
, pp. 213-223
-
-
Benzer, J.A.1
-
3
-
-
84876731120
-
Anti-hiv drug development: Structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment
-
Kumari G, Singh RK. Anti-HIV drug development: Structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment. Curr Pharmaceut Design 2013;19:1767-1783.
-
(2013)
Curr Pharmaceut Design
, vol.19
, pp. 1767-1783
-
-
Kumari, G.1
Singh, R.K.2
-
4
-
-
0037624182
-
Twenty years of therapy for HIV-1 infection
-
Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003;9:867-873.
-
(2003)
Nat Med
, vol.9
, pp. 867-873
-
-
Pomerantz, R.J.1
Horn, D.L.2
-
5
-
-
36749088862
-
Hiv drug development: The next 25 years
-
Flexner C. HIV drug development: The next 25 years. Nat Rev Drug Discov 2007;6:959-966.
-
(2007)
Nat Rev Drug Discov
, vol.6
, pp. 959-966
-
-
Flexner, C.1
-
6
-
-
84905646069
-
Compressed tablet formulation
-
Batra U, et al. Compressed tablet formulation. US Patent US7707294; 2006.
-
(2006)
US Patent US7707294
-
-
Batra, U.1
-
7
-
-
36849020049
-
Investigation of human pharmacoscintigraphy behaviour of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz
-
Gao JZ, et al. Investigation of human pharmacoscintigraphy behaviour of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). J Pharm Sci 2007;96:2970-2977.
-
(2007)
J Pharm Sci
, vol.96
, pp. 2970-2977
-
-
Gao, J.Z.1
-
9
-
-
84905664418
-
Development of Atripla® a fixed dose combination tablet of three drugs: Efavirenz emtricitabine and tenofovir disoproxil fumarate
-
Presented at
-
Hussain MA, et al. Development of Atripla® , a fixed dose combination tablet of three drugs: Efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Presented at AAPS Annual Meeting, New Orleans, LA, USA; 2010.
-
(2010)
AAPS Annual Meeting New Orleans la USA
-
-
Hussain, M.A.1
-
10
-
-
84905646070
-
Dry granulated composition comprising emtricitabine and tenofovir disoproxil fumarate
-
Dahl TC et al. Dry granulated composition comprising emtricitabine and tenofovir disoproxil fumarate European patent specification EP1890681 2009
-
(2009)
European Patent Specification EP1890681
-
-
Dahl, T.C.1
-
11
-
-
77954618054
-
One-pill once-A-day haart: A simplification strategy that improves adherence and quality of life in hiv-infected patients
-
Airoldi M et al. One-pill once-A-day haart: A simplification strategy that improves adherence and quality of life in hiv-infected patients. Patient Prefer Adherence, 2010, 4 115-125
-
(2010)
Patient Prefer Adherence
, vol.4
, pp. 115-125
-
-
Airoldi, M.1
-
12
-
-
78650039081
-
Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: Etravirine
-
Weuts I et al. Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: Etravirine.J Pharm Sci 2011 100 260-274
-
(2011)
J Pharm Sci
, vol.100
, pp. 260-274
-
-
Weuts, I.1
-
13
-
-
73949154387
-
An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature
-
Qi S et al. An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature. J Pharm Sci. 2010. 99.196-208
-
(2010)
J Pharm Sci
, vol.99
, pp. 196-208
-
-
Qi, S.1
-
14
-
-
61349103126
-
Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers
-
Kakuda TN et al. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med, 2009, 10, 173-181
-
(2009)
HIV Med
, vol.10
, pp. 173-181
-
-
Kakuda, T.N.1
-
16
-
-
84905655133
-
Beads having a core coated with an antifungal and a polymer
-
Gilis P.M.V. et al. Beads having a core coated with an antifungal and a polymer,US patent 5633015, 1997
-
(1997)
US Patent 5633015
-
-
Gilis, P.M.V.1
-
17
-
-
84905673466
-
HIV replication inhibiting pyrimidines
-
De Corte B et al.HIV replication inhibiting pyrimidines, US patent 7037197, 2006
-
(2006)
US Patent 7037197
-
-
De Corte, B.1
-
18
-
-
84905673467
-
Process for preparing spray dried formulation of TMC125
-
Kiekens FRI et al. Process for preparing spray dried formulation of TMC125. US patent application 2009/0197903, 2009
-
(2009)
US Patent Application 2009/0197903
-
-
Fri, K.1
-
19
-
-
49949104484
-
Single and multipledose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients
-
Kakuda TN et al. Single and multipledose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antiviral Ther, 2008, 1,655-661
-
(2008)
Antiviral Ther
, vol.1
, pp. 655-661
-
-
Kakuda, T.N.1
-
20
-
-
84886012661
-
Discovery and development of HIV-1entry inhibitors that target gp120
-
In (Kazmierski WM, Ed Hoboken, NJ, USA Wiley
-
Kadow JF, et al. Discovery and development of HIV-1entry inhibitors that target gp120. In: Antiviral Drugs: From Basic Discovery Through to Clinical Trials (Kazmierski WM, Ed). Hoboken, NJ, USA: Wiley; 2011.
-
(2011)
Antiviral Drugs: From Basic Discovery Through to Clinical Trials
-
-
Kadow, J.F.1
-
22
-
-
84905646068
-
Stable pharmaceutical composition for optimized delivery of an HIV attachment inhibitor
-
Brown JR et al. Stable pharmaceutical composition for optimized delivery of an HIV attachment inhibitor. European patent specification EP 2323633, 2012
-
(2012)
European Patent Specification EP 2323633
-
-
Brown, J.R.1
-
23
-
-
84877927926
-
Compartmental absorption modeling and site of absorption studies to determine feasibility of an extendedrelease formulation of an HIV-1 attachment inhibitor phosphate ester prodrug
-
Brown J et al. Compartmental absorption modeling and site of absorption studies to determine feasibility of an extendedrelease formulation of an HIV-1 attachment inhibitor phosphate ester prodrug. J Pharm Sci.2013. 102. 1742-1751
-
(2013)
J Pharm Sci
, vol.102
, pp. 1742-1751
-
-
Brown, J.1
-
24
-
-
84979509546
-
Investigation into the potential for prodrug hydrolysis within a hydrated HPMC matrix
-
Edinburgh, UK
-
Hanley S, et al. Investigation into the potential for prodrug hydrolysis within a hydrated HPMC matrix. Presented at APS PharmSci Conference, Edinburgh, UK; 2013.
-
(2013)
Presented at APS PharmSci Conference
-
-
Hanley, S.1
-
25
-
-
84868545732
-
The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate
-
Van den Mooter G. The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate. Drug Discov Today: Technologies 2012;9:e79-e85.
-
(2012)
Drug Discov Today: Technologies
, vol.9
, pp. 79-85
-
-
Van Den Mooter, G.1
-
26
-
-
84884140474
-
Melt extrusion with poorly soluble drugs
-
Shah S, et al. Melt extrusion with poorly soluble drugs. Int J Pharm 2013;453:233-252.
-
(2013)
Int J Pharm
, vol.453
, pp. 233-252
-
-
Shah, S.1
-
27
-
-
0014982253
-
Hot extruded dosage forms. Part 1: Technology and dissolution of polymeric matrices
-
El-Agakey MA, et al. Hot extruded dosage forms. Part 1: Technology and dissolution of polymeric matrices. Pharm Acta Helv 1971;46:31-52.
-
(1971)
Pharm Acta Helv
, vol.46
, pp. 31-52
-
-
El-Agakey, M.A.1
-
28
-
-
0031869733
-
Solid dispersions by an integrated melt extrusion system
-
Breitenbach J et al. Solid dispersions by an integrated melt extrusion system. Proc Intl Symp Control Rel Bioactive Mater. 1998. 25. 804-805
-
(1998)
Proc Intl Symp Control Rel Bioactive Mater
, vol.25
, pp. 804-805
-
-
Breitenbach, J.1
-
29
-
-
84875904527
-
-
EMA 27 April Downloaded on 9 October 2013 from
-
EMA. Kaletra, Scientific Discussion, 27 April 2006. Downloaded on 9 October 2013 from www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/ medicines/00036 8/human-med-000867.jsp&mid=WC0b01 ac058001d124
-
(2006)
Kaletra and Scientific Discussion
-
-
-
30
-
-
33745929028
-
Melt extrusion can bring new benefits to HIV therapy: The example of Kaletra tablets
-
Breitenbach J. Melt extrusion can bring new benefits to HIV therapy: The example of Kaletra tablets. Am J Drug Deliv. 2006. 4. 61-64
-
(2006)
Am J Drug Deliv
, vol.4
, pp. 61-64
-
-
Breitenbach, J.1
-
31
-
-
34147176581
-
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect
-
Klein CE et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007. 44. 401-410
-
(2007)
J Acquir Immune Defic Syndr
, vol.44
, pp. 401-410
-
-
Klein, C.E.1
-
32
-
-
84905664415
-
-
EMA 21 March 2013 Downloaded on 18 October 2013 from
-
EMA. Committee for Medicines for Human Use, Assessment Report: Stribild, 21 March 2013. Downloaded on 18 October 2013 from www.ema.europa.eu/ema/index. jsp?curl= pages/medicines/human/medicines/00257 4/human-med-001654.jsp&mid= WC0b01 ac058001d124
-
Committee for Medicines for Human Use, Assessment Report: Stribild
-
-
-
33
-
-
84905664416
-
Use of solid carrier particles to improve the processability of a pharmaceutical agent
-
Kozlara JM et al.Use of solid carrier particles to improve the processability of a pharmaceutical agent. US patent application US 2009/0324729. 2009
-
(2009)
US Patent Application US 2009/0324729
-
-
Kozlara, J.M.1
-
34
-
-
0033384441
-
Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers
-
Lamson MJ, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos 1999;20:285-291.
-
(1999)
Biopharm Drug Dispos
, vol.20
, pp. 285-291
-
-
Lamson, M.J.1
-
35
-
-
33846272175
-
Once-daily nevirapine dosing: A pharmacokinetics, efficacy and safety review
-
Cooper CL van Heeswijk RP. Once-daily nevirapine dosing: A pharmacokinetics, efficacy and safety review. HIV Med. 2007. 8. 1-7
-
(2007)
HIV Med
, vol.8
, pp. 1-7
-
-
Cooper, C.L.1
Van Heeswijk, R.P.2
-
36
-
-
84865796028
-
Predicting feasibility and characterizing performance of extendedrelease formulations using physiologically based pharmacokinetic modelling
-
Brown J et al.Predicting feasibility and characterizing performance of extendedrelease formulations using physiologically based pharmacokinetic modeling. Therapeut Deliv. 2012.3. 1047-1059
-
(2012)
Therapeut Deliv
, vol.3
, pp. 1047-1059
-
-
Brown, J.1
-
37
-
-
71449125747
-
Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract
-
Macha S et al. Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract. J Clin Pharmacol.2009. 49.1417-1425
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 1417-1425
-
-
Macha, S.1
-
38
-
-
79959756040
-
Evaluation of human regional bioavailability to assess whether modified release development is feasible
-
Presented at San Diego CA, USA
-
Connor A, et al. Evaluation of human regional bioavailability to assess whether modified release development is feasible. Presented at AAPS Annual Meeting, San Diego CA, USA; 2007.
-
(2007)
AAPS Annual Meeting
-
-
Connor, A.1
-
39
-
-
84905645991
-
Extended release formulation of nevirapine
-
Cappola ML et al. Extended release formulation of nevirapine. US patent US 8460704. 2013
-
(2013)
US Patent US 8460704
-
-
Cappola, M.L.1
-
40
-
-
73349133044
-
Vitro-in vivo correlation for nevirapine extended release tablets
-
Macha S, et al. In vitro-in vivo correlation for nevirapine extended release tablets. Biopharm Drug Dispos 2009;30:542-550.
-
(2009)
Biopharm Drug Dispos
, vol.30
, pp. 542-550
-
-
Macha, S.1
-
41
-
-
80053006457
-
Bioavailability of extended-release nevirapine 400 and 30 mg in HIV-1: A multicenter, open-label study
-
Battegay M et al. Bioavailability of extended-release nevirapine 400 and 30 mg in HIV-1: A multicenter, open-label study. Clin Ther. 2011. 33. 1308-1320
-
(2011)
Clin Ther
, vol.33
, pp. 1308-1320
-
-
Battegay, M.1
-
42
-
-
0001474469
-
Nevirapine induces both cyp3a4 and cyp2b6 metabolic pathways
-
Lamson M, et al. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin Pharm Ther 1999;65:137.
-
(1999)
Clin Pharm Ther
, vol.65
, pp. 137
-
-
Lamson, M.1
|